The U.S. Food and Drug Administration cited local generic drug giant Mylan for "significant violations" of manufacturing regulations at three plants in India, according to a warning letter released by the agency.
The FDA conducted inspections at the plants in August and September last year and in February of this year.
Some of the violations cited were failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products — including the use of torn gloves — and poor monitoring of personnel.
“Several violations are recurrent and long-standing,” the letter said.
The warning letter, dated Aug. 6, stated that Mylan had 15 working days to respond by outlining corrective measures or the FDA can withhold approval of new drug applications and block products coming to the U.S.
The warning letter "has no material impact on Mylan's business or its previously announced full year earnings guidance," Mylan said in a statement today.
“We have been and will continue to work diligently to address all of the FDA’s observations and have made important progress,” CEO Heather Bresch said in the statement.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.